ThermoGenesisHoldingsInc . (NASDAQ:THMO) Rating Increased to Buy at ValuEngine

Share on StockTwits

ThermoGenesisHoldingsInc . (NASDAQ:THMO) was upgraded by ValuEngine from a “hold” rating to a “buy” rating in a report issued on Tuesday, ValuEngine reports.

Separately, HC Wainwright reaffirmed a “buy” rating and set a $7.50 price target on shares of ThermoGenesisHoldingsInc . in a report on Thursday, November 21st.

THMO stock traded up $0.10 during midday trading on Tuesday, reaching $4.80. 664 shares of the company’s stock traded hands, compared to its average volume of 87,724. The business has a 50-day moving average of $3.45. ThermoGenesisHoldingsInc . has a 1-year low of $2.35 and a 1-year high of $7.00. The stock has a market cap of $12.58 million, a P/E ratio of -1.34 and a beta of 1.02. The company has a current ratio of 1.96, a quick ratio of 1.36 and a debt-to-equity ratio of 1.16.

ThermoGenesisHoldingsInc . (NASDAQ:THMO) last released its quarterly earnings results on Tuesday, November 19th. The company reported ($0.78) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($0.12) by ($0.66). ThermoGenesisHoldingsInc . had a negative net margin of 89.98% and a negative return on equity of 87.88%. The business had revenue of $4.06 million for the quarter, compared to analyst estimates of $4.80 million. On average, sell-side analysts anticipate that ThermoGenesisHoldingsInc . will post -0.16 earnings per share for the current fiscal year.

ThermoGenesisHoldingsInc . Company Profile

ThermoGenesis Holdings, Inc develops, commercializes, and markets a range of automated technologies for cell-based therapies in the United States, China, rest of Asia, Europe, and internationally. The company operates through two segments, Clinical Development and Device. It offers AutoXpress System, an automated system for the isolation, collection and storage of hematopoietic stem cell concentrates derived from cord blood and peripheral blood; Point-of CareXpress System for the rapid, automated processing of autologous peripheral blood or bone marrow aspirate derived stem cells; CAR-TXpress System that addresses the critical unmet need for chemistry, manufacturing and controls improvement of the emerging CAR-T therapies for cancer patients; BioArchive Cryopreservation System, an automated, robotic, liquid nitrogen controlled-rate-freezing and cryogenic storage system for stem cell samples and clinical products; and manual disposables.

Featured Article: How to Invest in an Index Fund

To view ValuEngine’s full report, visit ValuEngine’s official website.

Receive News & Ratings for ThermoGenesisHoldingsInc . Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ThermoGenesisHoldingsInc . and related companies with's FREE daily email newsletter.